(Q33878168)

29 July 2017

1 reference

title

Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping (English)

1 reference

29 July 2017

Prodinger WM

1

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

1 reference

29 July 2017

20

1 reference

29 July 2017

3

1 reference

29 July 2017

187-194

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02790402

29 July 2017

0 references

cites work

Therapeutic inhibition of the complement system.

1 reference

12 December 2020

Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23

1 reference

12 December 2020

Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

1 reference

12 December 2020

Follicular dendritic cells and human immunodeficiency virus infectivity

1 reference

12 December 2020

Role of Epstein-Barr virus and soluble CD21 in persistent polyclonal B-cell lymphocytosis

1 reference

12 December 2020

Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

1 reference

12 December 2020

Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes

1 reference

12 December 2020

Suppression of the Immune Response by a Soluble Complement Receptor of B Lymphocytes

1 reference

12 December 2020

Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response.

1 reference

12 December 2020

Three-dimensional structure of a complement control protein module in solution

1 reference

12 December 2020

Therapeutic uses of recombinant complement protein inhibitors

1 reference

12 December 2020

The role of complement and complement receptors in induction and regulation of immunity.

1 reference

12 December 2020

The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity

1 reference

12 December 2020

Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2)

1 reference

12 December 2020

Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen

1 reference

12 December 2020

Human epithelial cell expression of an Epstein-Barr virus receptor

1 reference

12 December 2020

The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity

1 reference

12 December 2020

Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

1 reference

12 December 2020

A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells

1 reference

12 December 2020

Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes

1 reference

12 December 2020

Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1.

1 reference

12 December 2020

Follicular dendritic cells specifically express the long CR2/CD21 isoform

1 reference

12 December 2020

Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules

1 reference

12 December 2020

Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes

1 reference

12 December 2020

Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).

1 reference

12 December 2020

Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2

1 reference

12 December 2020

Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d

1 reference

12 December 2020

Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus

1 reference

12 December 2020

CD23 and B-cell activation

1 reference

12 December 2020

X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2

1 reference

12 December 2020

In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody.

1 reference

12 December 2020

CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21

1 reference

12 December 2020

Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction

1 reference

12 December 2020

Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins

1 reference

12 December 2020

First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen

1 reference

12 December 2020

A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.

1 reference

12 December 2020

Determination of soluble CD21 as a parameter of B cell activation

1 reference

12 December 2020

Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).

1 reference

12 December 2020

Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody

1 reference

12 December 2020

OKB7, a monoclonal antibody that reacts at or near the C3d binding site of human CR2.

1 reference

12 December 2020

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

1 reference

12 December 2020

Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats

1 reference

12 December 2020

Expression in insect cells of the functional domain of CD21 (complement receptor type two) as a truncated soluble molecule using a baculovirus vector

1 reference

12 December 2020

Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia

1 reference

12 December 2020

Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).

1 reference

12 December 2020

Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis

1 reference

12 December 2020

Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis

1 reference

12 December 2020

Solution structure of a pair of complement modules by nuclear magnetic resonance

1 reference

12 December 2020

Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction

1 reference

12 December 2020

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2

1 reference

12 December 2020

Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement

1 reference

12 December 2020

Complement system proteins which interact with C3b or C4b A superfamily of structurally related proteins

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02790402

1 reference

PubMed ID

10741859

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10741859